# US 2016/0258933 A1 · Methods of determining cellular chemosensitivity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0258933 A1
- Document ID: US20160258933A1
- Status: Published application
- Kind: A1
- Application number: 15/073,391
- Filed: 2016-03-17
- Published: 2016-09-08
- Earliest claimed: 2006-03-31
- Assignees: Dana-Farber Cancer Institute, Inc.
- Applicants: Dana-Farber Cancer Institute, Inc.
- Inventors: Anthony Letai
- Web page: https://patentgrep.com/patent/US20160258933A1

## CPC

- G01N 33/5011: {for testing antineoplastic activity}
- A61P 35/00: Antineoplastic agents
- C12N 15/1037: {Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display}
- C12Q 1/025: {for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics (antimicrobial activity C12Q1/18)}
- G01N 33/521: {Single-layer analytical elements}
- G01N 33/575: for cancer
- G01N 33/57575: {involving oncogenic proteins}
- G01N 2510/00: Detection of programmed cell death, i.e. apoptosis
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present invention provides methods of determining cell sensitivity to a therapeutic agent.

## Claims

### Claim 1

A composition comprising an isolated permeabilized cell containing:
a BH3 domain peptide of less than or equal to 50 amino acids in length, and
a mitochondrion.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the BH3 domain peptide is selected from a BID BH3 domain, a BIM BH3 domain, a BAD BH3 domain, a BIK BH3 domain, a NOXA BH3 domain, a PUMA BH3 domain, a BMF BH3 domain, and an HRK BH3 domain.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the BH3 domain peptide contains an amino acid sequence selected from SEQ ID NOs: 1-11.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the cell is permeabilized by being contacted with digitonin.

### Claim 5 (depends on 1)

The composition of claim 1, wherein the BH3 domain peptide is less than or equal to 35 amino acids in length, less than or equal to 25 amino acids in length, or less than or equal to 15 amino acids in length.

### Claim 6 (depends on 1)

The composition of claim 1, wherein the isolated BH3 domain peptide is complexed with BCL-2, BCL-XL, MCL-1, BFL-1 or BCL-w protein in the cell.

### Claim 7 (depends on 1)

The composition of claim 1, wherein the permeabilized cell is a cancer cell.

### Claim 8 (depends on 7)

The composition of claim 7, wherein the cancer cell overexpresses BCL-2, BCL-XL, MCL-1, BFL-1 or BCL-w protein.

### Claim 9 (depends on 7)

The composition of claim 7, wherein the cancer cell is a lymphoma cell, a leukemia cell, or a small cell lung cancer cell.

### Claim 10 (depends on 1)

The composition of claim 1, wherein the isolated cell further contains a potentiometric dye.

### Claim 11 (depends on 10)

The composition of claim 10, wherein the potentiometric dye is JC-1.

### Claim 12

A composition comprising an isolated permeabilized cell contacted with an isolated BH3 domain peptide of less than or equal to 50 amino acids in length, wherein the isolated permeabilized cell contains a mitochondrion.

### Claim 13 (depends on 12)

The composition of claim 12, wherein the BH3 domain peptide is selected from a BID BH3 domain, a BIM BH3 domain, a BAD BH3 domain, a BIK BH3 domain, a NOXA BH3 domain, a PUMA BH3 domain, a BMF BH3 domain, and an HRK BH3 domain.

### Claim 14 (depends on 12)

The composition of claim 12, wherein the BH3 domain peptide contains an amino acid sequence selected from SEQ ID NOs: 1-11.

### Claim 15 (depends on 12)

The composition of claim 12, wherein the cell is permeabilized by being contacted with digitonin.

### Claim 16 (depends on 12)

The composition of claim 12, wherein the isolated BH3 domain peptide is complexed with CL-2, BCL-XL, MCL-1, BFL-1 or BCL-w protein in the cell.

### Claim 17 (depends on 12)

The composition of claim 12, wherein the permeabilized cell is a cancer cell.

### Claim 18 (depends on 17)

The composition of claim 17, wherein the cancer cell overexpresses BCL-2, BCL-XL, MCL-1, BFL-1 or BCL-w protein.

### Claim 19 (depends on 17)

The composition of claim 17, wherein the cancer cell is a lymphoma cell, a leukemia cell, or a small cell lung cancer cell.

### Claim 20 (depends on 12)

The composition of claim 12, wherein the isolated cell is further contacted with a potentiometric dye.

### Claim 21 (depends on 20)

The composition of claim 20, wherein the potentiometric dye is JC-1.

### Claim 22

A composition comprising an isolated permeabilized cell containing:
a complex of BCL-2, BCL-XL, MCL-1, BFL-1 or BCL-w protein and a BH3 domain peptide of less than or equal to 50 amino acids in length, and
a mitochondrion.

### Claim 23 (depends on 22)

The composition of claim 22, wherein the BH3 domain peptide is selected from a BID BH3 domain, a RIM BH3 domain, a BAD BH3 domain, a BIK BH3 domain, a NOXA BH3 domain, a PUMA BH3 domain, a BMF BH3 domain, and an HRK BH3 domain.

### Claim 24 (depends on 22)

The composition of claim 22, wherein the BH3 domain peptide contains an amino acid sequence selected from SEQ ID NOs: 1-11.

### Claim 25 (depends on 22)

The composition of claim 22, wherein the cell is permeabilized by being contacted with digitonin.

### Claim 26 (depends on 22)

The composition of claim 22, wherein the permeabilized cell is a cancer cell.

### Claim 27 (depends on 26)

The composition of claim 26, wherein the cancer cell overexpresses BCL-2, BCL-XL, MCL-1, BFL-1 or BCL-w protein.

### Claim 28 (depends on 26)

The composition of claim 26, wherein the cancer cell is a lymphoma cell, a leukemia cell, or a small cell lung cancer cell.

### Claim 29 (depends on 22)

The composition of claim 22, wherein the isolated cell further contains a potentiometric dye.

### Claim 30 (depends on 29)

The composition of claim 29, wherein the potentiometric dye is JC-1.
